Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4858542 | 0.99 | MAPT (0.49) | MAPTALDH1A1RXFP1NPSR1SMN1; SMN2 | |
| SCHEMBL6034938 | 0.92 | ALDH1A1 (0.50) | MAPTALDH1A1RXFP1NPSR1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4857202 | 0.91 | ADRB2 (0.51) | MAPTALDH1A1RXFP1NPSR1KDM4E | |
| SCHEMBL6034940 | 0.86 | ALDH1A1 (0.56) | MAPTALDH1A1NPSR1POLBKDM4E | |
| SCHEMBL6035910 | 0.86 | ALDH1A1 (0.51) | MAPTALDH1A1RXFP1NPSR1SMN1; SMN2 | |
| SCHEMBL6034819 | 0.86 | ALDH1A1 (0.57) | MAPTALDH1A1RXFP1SMN1; SMN2GAA | |
| Hydrochloric Acid SCHEMBL4860542 | 0.85 | ALDH1A1 (0.55) | MAPTALDH1A1NPSR1POLBKDM4E | |
| SCHEMBL6035994 | 0.85 | ALDH1A1 (0.53) | MAPTALDH1A1RXFP1NPSR1KDM4E | |
| Hydrochloric Acid SCHEMBL4852328 | 0.85 | ALDH1A1 (0.51) | MAPTALDH1A1RXFP1NPSR1SMN1; SMN2 | |
| SCHEMBL6035341 | 0.85 | ALDH1A1 (0.53) | MAPTALDH1A1RXFP1NPSR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| US-20060063769-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063769-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, CHRM1 | MAPT 1965/4885ALDH1A1 118/4885RXFP1 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.